Rexahn Pharmaceuticals Forecasted to Post FY2018 Earnings of ($0.70) Per Share (RNN)

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) – Stock analysts at Seaport Global Securities dropped their FY2018 EPS estimates for shares of Rexahn Pharmaceuticals in a note issued to investors on Monday, May 14th. Seaport Global Securities analyst V. Bernardino now anticipates that the company will post earnings per share of ($0.70) for the year, down from their prior estimate of ($0.50).

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last released its quarterly earnings results on Monday, May 7th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04).

RNN has been the topic of a number of other reports. HC Wainwright set a $20.00 price target on shares of Rexahn Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, March 12th. Zacks Investment Research lowered shares of Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 10th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Rexahn Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $13.75.

Rexahn Pharmaceuticals opened at $2.15 on Thursday, MarketBeat Ratings reports. Rexahn Pharmaceuticals has a 52 week low of $2.10 and a 52 week high of $2.12.

An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Northern Trust Corp boosted its position in shares of Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) by 61.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 77,213 shares of the company’s stock after buying an additional 29,354 shares during the period. Northern Trust Corp owned approximately 0.24% of Rexahn Pharmaceuticals worth $117,000 at the end of the most recent quarter.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit